Type-2 diabetes mellitus (T2DM) is the leading cause of premature deaths. It can be improperly managed, leading to several health issues such as heart diseases, stroke, kidney disease, blindness, nerve damage, leg and foot amputations, and death. 1 Linagliptin is recently added to incretin-based therapies demonstrated adequate efficacy and a favorable safety profile, especially cardiovascular and renal safety. 2 In this regard, Boehringer Ingelheim India and Docplexus have organized an International Speaker Webinar Program on 30 th November 2020 from 04:00 PM IST onwards.
In this webinar, the International expert panel (Dr. Michael Cummings and Dr. (Prof.) Per-Henrik Groop) will provide an intensive and insightful discussion on a simple and effective perspective of T2DM Care. We invite you to share your questions which will be answered by the experts at the end of the session.…
